Elevated Expression of Vascular Adhesion Molecule-1, Plasminogen Activator Inhibitor-1, Cyclooxygenase-2, and Thrombomodulin in Human Umbilical Vein Endothelial Cells from Hospitalized Gestational Diabetes Mellitus Patients.
August 7, 2020

Elevated Expression of Vascular Adhesion Molecule-1, Plasminogen Activator Inhibitor-1, Cyclooxygenase-2, and Thrombomodulin in Human Umbilical Vein Endothelial Cells from Hospitalized Gestational Diabetes Mellitus Patients.

By Alyssa

protein expression in human umbilical vein endothelial cells (HUVECs) is a useful indicator of the condition of the mother during pregnancy and the intrauterine environment. Therefore, we examined the protein expression in HUVECs were obtained from patients with gestational diabetes mellitus (GDM). HUVECs were made from the umbilical cord and control GDM patients undergoing planned caesarean section between 2013 and 2014 at Teikyo University Hospital (Tokyo, Japan).

There was no difference in blood glucose levels between patients with GDM and control the time of entry. However, body mass index, pre-pregnancy (BMI) were higher in GDM patients, although changes in pregnancy BMI smaller during hospitalization. To evaluate the state of the endothelium, we examined the protein expression levels of vascular adhesion molecule-1 (VCAM-1), an adhesion molecule-1, thrombomodulin (TM), endothelial nitric oxide synthase, plasminogen activator inhibitor-1 (PAI- 1), siklooksigenase- 2 (COX-2), and VE-cadherin, which is changed by various factors in the endothelial tissue.

VCAM-1, PAI-1 and COX-2 expression was higher in HUVECs of patients with GDM compared to controls. Due to pre-pregnancy BMI was higher in patients with GDM, we examined the relationship between BMI and protein expression. However, the protein expression levels are not correlated with pre-pregnancy BMI and higher in HUVECs of GDM patients than other BMI of BMI-matched controls.

Interestingly, the expression of TM was also higher in HUVECs of BMI-matched patients with GDM. Thus, the expression of VCAM-1, PAI-1, COX-2, and TM may reflect certain factors are altered intrauterine environment in GDM patients hospitalized with weight under control.

Elevated Expression of Vascular Adhesion Molecule-1, <em>Plasminogen</em> <em>Activator</em> <em>Inhibitor</em>-1, Cyclooxygenase-<em>2</em>, and Thrombomodulin in Human Umbilical Vein Endothelial Cells from Hospitalized Gestational Diabetes Mellitus Patients.
Elevated Expression of Vascular Adhesion Molecule-1, Plasminogen Activator Inhibitor-1, Cyclooxygenase-2, and Thrombomodulin in Human Umbilical Vein Endothelial Cells from Hospitalized Gestational Diabetes Mellitus Patients.

Plasminogen driving inhibitors – two the development of excess bladder cancer support ( two PAI- ) in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl) -nitrosamine- induced rat model of bladder cancer.

Collecting evidence suggests that the plasminogen activator inhibitor-1 (PAI-1) play an important role in bladder tumorigenesis by regulating the cell cycle. However, it remains unclear whether and how the inhibition of PAI-1 Pressing bladder tumorigenesis.To explain the therapeutic effect of PAI-1 inhibition, we tested the tumorigenicity in PAI-1 knockout (KO) mice exposed to bladder known carcinogen.PAI- 1 deficiency is not inhibit carcinogen-induced bladder cancer in carcinogen-exposed rats although wild-type mice significantly increased PAI-1 levels in bladder tissue, plasma and urine.

We found that PAI-1 KO mice exposed to carcinogens tend to upregulate protein C inhibitor (PAI-3), urokinase-type plasminogen activator (uPA) and tissue-type PA (TPA), and significantly increased PAI-2, indicating the potential compensation function of these molecules when PAI-1 was canceled. subsequent studies using gene expression microarray using bladder tissue of mice followed by post hoc bioinformatics analysis and validation experiments by qPCR and IHC showed that SERPING1 subsequently downregulated in PAI-1 KO mice exposed to BBN, suggesting that SERPING1 as a potential factor is missing which regulate PAI – 2 excess (track compensation) .

Cat IgG Fab2-Biotin conjugate (non-immune, isotype control) purified

20002-4-B 0.1 mg
EUR 225

Cat IgG Fab2-FITC conjugate (non-immune, isotype control) purified

20002-4-F 0.1 mg
EUR 225

Cat IgG Fab2-HRP conjugate (non-immune, isotype control) purified

20002-4-HP 0.1 mg
EUR 225

Cat IgG Fab2, unlabeled (non-immune, isotype control) purified

20002-4-UL 0.1 mg
EUR 164

Cat IgM-Biotin conjugate (non-immune, isotype control) purified

20002-5-B 0.1 mg
EUR 225

Cat IgM, unlabeled (non-immune, isotype control) purified

20002-5-UL 0.1 mg
EUR 164

FluoroQuest™ Anti-fading Kit II *Optimized for Plate Imaging*

20003 1 kit
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200

Hamster IgG, purified (Syrian, isotype control)

20003-1 1 mg
EUR 141

Hamster IgG-Biotin conjugate, isotype control (Syrian)

20003-1-B 100 test
EUR 164

Hamster IgG-Cy5 conjugate, isotype control (Syrian)

20003-1-Cy5 50 tests
EUR 225

Hamster IgG-FITC conjugate, isotype control (Syrian)

20003-1-F 100 tests
EUR 164

Hamster IgG-HRP conjugate, isotype control (Syrian)

20003-1-HP 100 tests
EUR 164

Hamster IgG-R-PE-Cy5.5 conjugate, isotype control (Syrian)

20003-1-PC5 50 tests
EUR 250

Hamster IgG-R-PE conjugate, isotype control (Syrian)

20003-1-PE 50 tests
EUR 225

Hamster IgG, purified (Armenian, Isotype control)

20003-1AH 1 mg
EUR 263

Hamster (Syrian, non-immune) Serum IgM, purified (Syrian)

20003-2-1 0.5 mg
EUR 225

FluoroQuest™ Mounting Medium with DAPI

20004 50 mL
EUR 132
  • R-phrase: R20, R21, R68
  • H-Phrase: H303, H313, H340
  • Symbol for dangerous compounds: T
  • UNSPEC Code: 12352200

G. Pig IgG, purified (non-immune, serum, Isotype control)

20004-1 1 mg
EUR 141

G. Pig IgM, purified (non-immune, serum, Isotype control)

20004-2-1 0.5 mg
EUR 225

G. Pig IgG Fc-Biotin conjugate (isotype control, non-immune) purified

20004-3-B 0.1 mg
EUR 225

G. Pig IgG Fc-FITC conjugate (isotype control, non-immune) purified

20004-3-F 0.1 mg
EUR 225

G. Pig IgG Fc-HRP conjugate (isotype control, non-immune) purified

20004-3-HP 0.1 mg
EUR 225

G. Pig IgG Fc unlabeled (isotype control, non-immune) purified

20004-3-UL 0.5 mg
EUR 202

G. Pig IgA, purified (non-immune, serum, Isotype control)

20004-5-1 100 ug
EUR 347

G. Pig IgG-Biotin conjugate (isotype control)

20004-B 100 ug
EUR 202

G. Pig IgG-FITC conjugate (isotype control)

20004-F 100 ug
EUR 202

G. Pig IgG-HRP conjugate (isotype control)

20004-HP 100 ug
EUR 202

Rat IgG, purified (Whole, non-immune) (isotype control)

20005-1 1 mg
EUR 141

Rat IgG purified (isotype control)

20005-1-200 0.5 ml
EUR 103

Rat IgG Fab fragment, purified (isotype control)

20005-1-FAB 1 mg
EUR 164

Rat IgG F(ab')2 fragment, purified (isotype control)

20005-1-FAB2 1 mg
EUR 202

Rat IgG (Fc) fragment, purified (isotype control)

20005-1-FC 0.5 mg
EUR 250

Rat IgG (Fc)-Biotin Conjuagte (isotype control), purified

20005-1-FC-B 0.1 mg
EUR 225

Rat IgG (Fc)-FITC Conjuagte (isotype control), purified

20005-1-FC-F 0.1 mg
EUR 225

Rat IgG (Fc)-HRP Conjuagte (isotype control), purified

20005-1-FC-HP 0.1 mg
EUR 225

Rat IgG, purified (Whole, non-immune) (isotype control)

20005-10 10 mg
EUR 408

Rat IgG1 cunonjugated (isotype control)

20005-11 100 ug
EUR 164

Rat IgG1-Biotin conjugate (isotype control)

20005-11-B 100 ug
EUR 202

Rat IgG1-FITC conjugate (isotype control)

20005-11-F 100 ug
EUR 225

Rat IgG1-HRP conjugate (isotype control)

20005-11-HP 100 ug
EUR 202

Rat IgG1-R-PE-Cy5.5 conjugate (isotype control)

20005-11-PC5 25 tests
EUR 202

Rat IgG1-R-PE conjugate (isotype control)

20005-11-PE 25 tests
EUR 202

Rat IgG2a unconjugated (isotype control)

20005-12 100 ug
EUR 164

Rat IgG2a-APC conjugate (isotype control)

20005-12-APC 25 tests
EUR 202

Rat IgG2a-Biotin conjugate (isotype control)

20005-12-B 100 ug
EUR 202

Rat IgG2a-FITC conjugate (isotype control)

20005-12-F 100 ug
EUR 225

Rat IgG2a-HRP conjugate (isotype control)

20005-12-HP 100 ug
EUR 202

Rat IgG2a-R-PE-Cy5.5 conjugate (isotype control)

20005-12-PC5 25 tests
EUR 213

Rat IgG2a-R-PE conjugate (isotype control)

20005-12-PE 25 tests
EUR 202

Rat IgG2b unconjugated (isotype control)

20005-13 100 ug
EUR 164

Rat IgG2b-Biotin conjugate (isotype control)

20005-13-B 100 ug
EUR 202

Rat IgG2b-FITC conjugate (isotype control)

20005-13-F 100 ug
EUR 225

Rat IgG2b-HRP conjugate (isotype control)

20005-13-HP 100 ug
EUR 202

Rat IgG2b-R-PE-Cy5.5 conjugate (isotype control)

20005-13-PC5 25 tests
EUR 213

Rat IgG2b-R-PE conjugate (isotype control)

20005-13-PE 25 tests
EUR 202

Rat IgG2c-Biotin conjugate (isotype control)

20005-14-B 100 ug
EUR 225

Rat IgG2c-FITC conjugate (isotype control)

20005-14-F 100 ug
EUR 225

Rat IgG2c-HRP conjugate (isotype control)

20005-14-HP 100 ug
EUR 225

Rat IgG2c-R-PE conjugate (isotype control)

20005-14-PE 50 tests
EUR 250

Rat IgG2c unonjugated (isotype control)

20005-14-UL 100 ug
EUR 164

Rat IgM (non-immune), purified (isotype control)

20005-2-1 0.1 mg
EUR 164

Rat IgM-Biotin conjugate (isotype control)

20005-21-B 100 ug
EUR 225

Rat IgM-FITC conjugate (isotype control)

20005-21-F 100 ug
EUR 225

Rat IgM-HRP conjugate (isotype control)

20005-21-HP 100 ug
EUR 225

Rat IgM-R-PE conjugate (isotype control)

20005-21-PE 25 tests
EUR 202

Rat IgA (non-immune), purified (isotype control)

20005-3-1 25 ug
EUR 225

Rat IgG, purified (Isotype control)

20005-5 5 mg
EUR 286

Rat IgG-Agarose conjugate(aff matrix)

20005-AS-1 0.5 ml
EUR 164

Rat IgG-Biotin conjugate (isotype control) (Isotype control)

20005-B 100 ug
EUR 164

Rat IgG-FITC conjugate (isotype control) (Isotype control)

20005-F 100 ug
EUR 164

Rat IgG-HRP conjugate (isotype control) (Isotype control)

20005-HP 100 ug
EUR 164

Rat IgG-PE conjugate (isotype control) (Isotype control)

20005-PE 25 tests
EUR 202

FluoroQuest™ Fluorescence Signal Enhancing Solution

20006 5 mL
EUR 132
  • R-phrase: R20, R21, R68
  • H-Phrase: H303, H313, H340
  • Symbol for dangerous compounds: T
  • UNSPEC Code: 12352200

Sheep IgG, purified (isotype control)

20006-1 1 mg
EUR 141

Sheep IgG-Biotin Conjugate (isotype control, non-immune), purified

20006-1-B 0.5 mg
EUR 202

Sheep IgG-FITC Conjugate (isotype control, non-immune), purified

20006-1-F 0.5 mg
EUR 202

Sheep IgG-HRP Conjugate (isotype control, non-immune), purified

20006-1-HP 0.5 mg
EUR 202

Sheep IgM purified (isotype control)

20006-2 1 mg
EUR 347

Sheep IgM-Biotin Conjugate (non-immune) control, purified

20006-2-B 0.1 mg
EUR 225

Sheep IgA purified (isotype control)

20006-3 100 ug
EUR 286

Sheep IgG Fc-Biotin Conjugate (isotype control, non-immune), purified

20006-4-B 0.5 mg
EUR 202

Sheep IgG Fc-FITC Conjugate (isotype control, non-immune), purified

20006-4-F 0.5 mg
EUR 202

Sheep IgG Fc-HRP Conjugate (isotype control, non-immune), purified

20006-4-HP 0.5 mg
EUR 202

Sheep IgG Fc unlabeled (isotype control, non-immune), purified

20006-4-UL 0.5 mg
EUR 202

Human IgG, purified (serum, non-immune, isotype control)

20007-1-1 1 mg
EUR 141

Human IgG, purified (serum, non-immune, isotype control)

20007-1-100 100 mg
EUR 895

Human IgG, purified (serum, non-immune, isotype control)

20007-1-25 25 mg
EUR 651

Human IgG, purified (serum, non-immune, isotype control)

20007-1-5 5 mg
EUR 286

Human IgG-Biotin conjugate (isotype control, non-immune), purified

20007-1-B 0.5 mg
EUR 225

Human IgG (>98%, non-immune, control, Liquid @ 10 mg/ml, azide free, bulk size)

20007-1-BL-1 10 ml Ask for price

Human IgG (>98%, non-immune, control, powder, azide free, bulk size)

20007-1-BP-1 1 g
EUR 651

Human IgG (>98%, non-immune, control, powder, azide free, bulk size)

20007-1-BP-10 10 g
EUR 4313

Human IgG-FITC conjugate (isotype control, non-immune), purified

20007-1-F 0.5 mg
EUR 225

Human IgG Fab fragment, purified

20007-1-FAB 1 mg
EUR 202

Human IgG Fab fragment-Biotin Conjugate, purified

20007-1-FAB-B 0.1 mg
EUR 202

Human IgG Fab fragment-FITC Conjugate, purified

20007-1-FAB-F 0.1 mg
EUR 202

Human IgG Fab fragment-HRP Conjugate, purified

20007-1-FAB-HP 0.1 mg
EUR 202

Human IgG F(ab')2 fragment, purified

20007-1-FAB2 1 mg
EUR 202

Human IgG Fab2 fragment-Biotin Conjugate, purified

20007-1-FAB2-B 0.1 mg
EUR 202

This result indicates that the compensation serpin lanes, particularly PAI-2 overproduction in this model, support the development of bladder cancer when oncoprotein PAI-1 is deleted. Further investigation into the PAI-1 is required to identify the true potential targets for therapy of bladder cancer.